Chandra Prakash1, Suchet Sachdev2, Neelam Marwaha3, Rekha Hans2. 1. M.Sc. Medical Technology (Transfusion Medicine), Department of Transfusion Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 2. Assistant Professor, Department of Transfusion Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 3. Senior Professor and Head, Department of Transfusion Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Abstract
BACKGROUND AND AIMS: The aim of the present study was to know the prevalence of viral hepatitis markers among blood donors deferred on the basis of a history of jaundice of unknown origin and to predict the impact of this deferral on blood safety. METHODS: Observational study included 200 blood donors deferred on the basis of a history of jaundice of unknown origin and carried out serology and Individual Donation Nucleic Acid Testing (ID-NAT) for hepatitis B and hepatitis C. RESULTS: Five (2.5%) out of 200 blood donors deferred on the basis of history of jaundice were reactive on ELISA. Three out of five were reactive for HBsAg; whereas two for anti-HCV antibodies. Out of the 12 ID-NAT initial reactive, 10 samples discriminated on further testing; 4 for HBV, 5 for HCV and 1 was co-infection (HBV + HCV). The odds of being picked up as sero reactive on ELISA was 2.53 (95% CI; 1.04-6.19) and being picked up as ID-NAT yield was 13.08 (95% CI; 5.29-32.37) in donors deferred on a history of jaundice of unknown origin as compared to selected donors without a history of jaundice, with the difference in means achieving statistically significance at P = 0.03 and <0.001 respectively.The potential of deferral on a history of jaundice of unknown origin has a capacity to interdict 2-3 HBV and/or HCV reactive blood donors on serology and 5 HBV and/or HCV reactive blood donors on ID-NAT from entering the quarantine blood supply per 100 donors. CONCLUSION: The findings of the present study support that a deferral for a history of jaundice of unknown origin after attaining the age of 12 years in the present scenario of transfusion transmissible infectious disease screening in India.
BACKGROUND AND AIMS: The aim of the present study was to know the prevalence of viral hepatitis markers among blood donors deferred on the basis of a history of jaundice of unknown origin and to predict the impact of this deferral on blood safety. METHODS: Observational study included 200 blood donors deferred on the basis of a history of jaundice of unknown origin and carried out serology and Individual Donation Nucleic Acid Testing (ID-NAT) for hepatitis B and hepatitis C. RESULTS: Five (2.5%) out of 200 blood donors deferred on the basis of history of jaundice were reactive on ELISA. Three out of five were reactive for HBsAg; whereas two for anti-HCV antibodies. Out of the 12 ID-NAT initial reactive, 10 samples discriminated on further testing; 4 for HBV, 5 for HCV and 1 was co-infection (HBV + HCV). The odds of being picked up as sero reactive on ELISA was 2.53 (95% CI; 1.04-6.19) and being picked up as ID-NAT yield was 13.08 (95% CI; 5.29-32.37) in donors deferred on a history of jaundice of unknown origin as compared to selected donors without a history of jaundice, with the difference in means achieving statistically significance at P = 0.03 and <0.001 respectively.The potential of deferral on a history of jaundice of unknown origin has a capacity to interdict 2-3 HBV and/or HCV reactive blood donors on serology and 5 HBV and/or HCV reactive blood donors on ID-NAT from entering the quarantine blood supply per 100 donors. CONCLUSION: The findings of the present study support that a deferral for a history of jaundice of unknown origin after attaining the age of 12 years in the present scenario of transfusion transmissible infectious disease screening in India.
Entities:
Keywords:
ELISA; ELISA, Enzyme Linked Immunosorbent Assay; HBV, Hepatitis B Virus; HCV, Hepatitis C Virus; ID NAT; ID NAT, Individual Donation Nucleic Acid Testing; jaundice of unknown origin
Authors: Shimian Zou; Karen Fujii; Stephanie Johnson; Bryan Spencer; Nicole Washington; Edward Notari Iv; Fatemeh Musavi; Bruce Newman; Ritchard Cable; Jorge Rios; Krista L Hillyer; Christopher D Hillyer; Roger Y Dodd Journal: Transfusion Date: 2006-11 Impact factor: 3.157